Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Form | Size | Price | $/mg | Stock | Updated |
|---|---|---|---|---|---|
| vial | 5mg | $50.00 | $10.00/mg | In stock | Jul 27 |
| vial | 10mg | $90.00 | $9.00/mg | In stock | Jul 27 |
| vial | 20mg | $170.00 | $8.50/mg | In stock | Jul 27 |
Single-vial list prices — bulk or bundle orders may be lower. Verify at vendor before purchase.
| Lot / Report | Tested | Purity | Lab | Panels | Status | |
|---|---|---|---|---|---|---|
| 665394 | Apr 2026 | — | Freedom Diagnostics | Endotoxin | Confirmed | View |
CJC-1295 and Ipamorelin acetate were not part of the April 2026 removal — both left 503A Category 2 earlier, on September 27, 2024, when their nominations were withdrawn. Ipamorelin acetate remains in 503B Category 2. Neither is in Category 1, neither is on the 503A bulks list, and neither is on the July 2026 PCAC docket, so neither is authorized for compounding.
Does Blank Peptides sell CJC-1295?
Yes — Blank Peptides currently lists CJC-1295 in 3 variants starting at $170.00 ($8.50/mg).
Is Blank Peptides's CJC-1295 third-party tested?
Yes — Disclosed Labs has indexed 1 Certificate of Analysis for Blank Peptides's CJC-1295. Blank Peptides holds an overall trust grade of B (80/100) across all 138 COAs on file.
What is Blank Peptides's trust grade for CJC-1295?
Blank Peptides has an overall Disclosed Labs trust grade of B (80/100), computed from 138 COAs across all peptides. The most recent CJC-1295 COA was issued by Freedom Diagnostics.
Where is the cheapest CJC-1295?
As of the latest data, Peptide Supply Co. offers CJC-1295 at $3.80/mg — compare with Blank Peptides's listing at $8.50/mg. See the full CJC-1295 price comparison.
What is the FDA compounding status of CJC-1295?
CJC-1295 and Ipamorelin acetate were not part of the April 2026 removal — both left 503A Category 2 earlier, on September 27, 2024, when their nominations were withdrawn. Ipamorelin acetate remains in 503B Category 2. Neither is in Category 1, neither is on the 503A bulks list, and neither is on the July 2026 PCAC docket, so neither is authorized for compounding. Sales tracked here are for research purposes only. Disclosed Labs does not provide medical or legal advice.
Disclosed Labs